Evidence map›Paper›PMID 22132895›Full record

ArticleClinical and experimental immunology2012

A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection.

V Tiriveedhi, N Angaswamy, D Brand, J Weber, A G Gelman, R Hachem, E P Trulock, B Meyers, G Patterson, T Mohanakumar

Open access · bronzeAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. [Immunological Aspects after Lung Transplantation].Zentralblatt fur Chirurgie · 2025
    Review
  4. Review
  5. Immune processes in the pathogenesis of chronic lung allograft dysfunction: identifying the missing pieces of the puzzle.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Community-acquired Respiratory Viruses Are a Risk Factor for Chronic Lung Allograft Dysfunction.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

V TiriveedhiDepartment of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA.
N Angaswamy
D Brand
J Weber
A G Gelman
R Hachem
E P Trulock
B Meyers
G Patterson
T Mohanakumar
Washington University in St. Louis · USBipar · FR

Funding

EXPERIMENTAL PATHOLOGY OF CARDIOVASCULAR DISEASET32HL007312 · NHLBI · UNIVERSITY OF WASHINGTON · PI MAJESKY, MARK W., SCHWARTZ, STEPHEN MARK · 1985 to 2019
$11.8M
IMMUNE MECHANISMS OF REJECTION IN HUMAN LUNG ALLOGRAFTSR01HL056643 · NHLBI · WASHINGTON UNIVERSITY · PI MOHANAKUMAR, THALACHALLOUR · 1996 to 2015
$6.5M
ALLOANTIBODIES TO MHC INDUCES AUTOIMMUNITY AND OBLITERATIVE AIRWAY DISEASE (OAD)R01HL092514 · NHLBI · WASHINGTON UNIVERSITY · PI MOHANAKUMAR, THALACHALLOUR · 2009 to 2018
$3.0M
NHLBI NIH HHS R01 HL056643NHLBI NIH HHS R01 HL092514NHLBI NIH HHS T32 HL007312
6 · The paper itself

Abstract

Immune responses to human leucocyte antigen (HLA) and self-antigen collagen V (Col-V) have been proposed in the pathogenesis of chronic rejection (bronchiolitis obliterans syndrome, BOS) following human lung transplantation (LTx). In this study, we defined the role for the shift in immunodominant epitopes of Col-V in inducing T helper phenotype switch leading to immunity to Col-V and BOS. Sera and lavage from BOS(+) LTx recipients with antibodies to Col-V were analysed. Two years prior to BOS, patients developed antibodies to both Col-V,α1(V) and α2(V) chains. However, at clinical diagnosis of BOS, antibodies became restricted to α1(V). Further, lung biopsy from BOS(+) patients bound to antibodies to α1(V), indicating that these epitopes are exposed. Fourteen Col-V peptides [pep1-14, pep1-4 specific to α1(V), pep5-8 to α1,2(V) and pep9-14 to α2(V)] which bind to HLA-DR4 and -DR7, demonstrated that prior to BOS, pep 6, 7, 9, 11 and 14 were immunodominant and induced interleukin (IL)-10. However, at BOS, the response switched to pep1, 4 and 5 and induced interferon (IFN)-γ and IL-17 responses, but not IL-10. The T helper (Th) phenotype switch is accompanied by decreased frequency of regulatory T cells (T(regs) ) in the lavage. LTx recipients with antibodies to α1(V) also demonstrated increased matrix metalloproteinase (MMP) activation with decreased MMP inhibitor, tissue inhibitor of metalloproteinase (TIMP), suggesting that MMP activation may play a role in the exposure of new Col-V antigenic epitopes. We conclude that a shift in immunodominance of self-antigenic determinants of Col-V results in induction of IFN-γ and IL-17 with loss of tolerance leading to autoimmunity to Col-V, which leads to chronic lung allograft rejection.

Indexed as

AdultAmino Acid SequenceAutoantigensBronchiolitis ObliteransCollagen Type ICollagen Type VDNA MethylationEnzyme ActivationFemaleFollow-Up StudiesForkhead Transcription FactorsGraft RejectionHumansImmunodominant EpitopesImmunophenotypingImmunosuppressive AgentsAutoantigensCollagen Type ICollagen Type VForkhead Transcription FactorsFOXP3 protein, humanImmunodominant EpitopesImmunosuppressive AgentsInterferon-gammaInterleukin-17IsoantigensMatrix Metalloproteinase 2Matrix Metalloproteinase 9MMP2 protein, humanPeptide Fragments

Identifiers

PMID22132895
PMCPMC3248097
OpenAlexW1532059102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.